Matthew Tall
Institute of Cancer Research(GB)
Publications by Year
Research Areas
Histone Deacetylase Inhibitors Research, Protein Degradation and Inhibitors, Epigenetics and DNA Methylation, PI3K/AKT/mTOR signaling in cancer, Peptidase Inhibition and Analysis
Most-Cited Works
- → A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors(2012)78 cited
- → The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma(2015)68 cited
- → Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors.(2011)19 cited
- → Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors.(2014)7 cited
- → Abstract CT111: Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial(2024)5 cited
- → A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of CHR-3996, a class 1 selective histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors.(2010)4 cited
- → Abstract 27: First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade(2010)3 cited
- → Abstract B044: Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors(2023)2 cited
- → Supplementary Materials from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors(2023)
- → Data from A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors(2023)